Mindmaze, a Swiss biotechnology company, is developing Mindmotion Lite, a tablet-based system designed to deliver intensive neurorehabilitation at home by the end of 2026. The platform leverages artificial intelligence and a proprietary DNA-inspired algorithm to streamline therapy, reducing hardware complexity compared to existing solutions. It will integrate all functionalities of Mindmotion GO—including guided exercises—alongside teleconsultations and remote monitoring by healthcare professionals.
Mindmotion Lite is intended to complement Mindmaze’s existing portfolio, accelerating the scaling of home-based neurorehabilitation. The company has not yet disclosed specific details about pricing, distribution, or regional availability, though it will provide updates closer to the launch date. While the platform’s core focus remains on accessibility and efficiency, its broader impact on the neurorehabilitation market remains to be seen.
